Market revenue in 2023 | USD 204.4 million |
Market revenue in 2030 | USD 338.2 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.42% in 2023. Horizon Databook has segmented the North America cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the cell & gene therapy bioanalytical testing services market and accounted for the largest revenue share of 40.4% in 2023. This can be attributed to the large number of cell and gene therapy clinical trials performed across the U.S.
The growing need for personalized medicine, rising investment in cell & gene therapy Research & Development (R&D), and rising incidence of genetic & chronic diseases are among the factors contributing to the market growth in the region.
Investments in cell and gene therapy R&D have significantly increased in the region. Cell and gene therapies provide personalized therapy choices specific to each patient's genetic composition and disease profile. The need for personalized medicine is rising in North America due to advancements in genomic technologies and a better understanding of diseases at the molecular level.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This continent databook contains high-level insights into North America cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account